Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035585 | 1.00 | HRH3 (0.73) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| Hydrochloric Acid SCHEMBL6473996 | 0.98 | HRH3 (0.71) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| SCHEMBL8337754 | 0.98 | HRH3 (0.70) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| Hydrochloric Acid SCHEMBL8972891 | 0.96 | HRH3 (0.68) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| SCHEMBL15834053 | 0.95 | HRH3 (0.66) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| SCHEMBL7447133 | 0.93 | HRH3 (0.73) | HRH3PSMB1PSMB5PSMB2MAPK14 | |
| SCHEMBL2827364 | 0.91 | HRH3 (0.75) | HRH3MAPK14KDM4E | |
| SCHEMBL10200146 | 0.91 | HRH3 (0.75) | HRH3MAPK14KDM4E | |
| SCHEMBL13246349 | 0.90 | HRH3 (0.73) | HRH3MAPK14 | |
| SCHEMBL2629440 | 0.89 | HRH3 (0.72) | HRH3MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6768024-B1 | CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION | LION BIOSCIENCE AG (DE) | 2004-07-27 | — | — | US | claimed |
| CN-116715657-A | Diaryl acetylene compound, preparation method and application thereof | 河南省锐达医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116675686-A | Isoindolinyl-piperidine carboxamide compound, and preparation method and application thereof | 河南省锐达医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116554158-A | Isoindolinyl-piperazinyl urea compound, and preparation method and application thereof | 河南省锐达医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| CN-113444035-B | Naphthyl urea compounds with anticancer effect and preparation method and application thereof | 河南省锐达医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-112961120-B | Naphthyl urea compound, preparation method and application thereof | 河南省锐达医药科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-10478443-B2 | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women | ENDORECHERCHE, INC. (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-6768024-B1 | CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION | LION BIOSCIENCE AG (DE) | 2004-07-27 | — | — | US | disclosed |
| EP-0832880-A1 | Dihydrobenzofluorene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0774966-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | LILLY CO ELI (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0774966-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996009040-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009039-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009051-A1 | A METHOD FOR MINIMIZING THE UTEROTROPHIC EFFECT OF TAMOXIFEN AND TAMOXIFEN ANALOGS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0703228-A1 | Naphthyl compounds, intermediates, processes, compositions involving them | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702961-A2 | Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702962-A2 | Preparations for inhibiting mammalian breast carcinoma with tamoxifen and analogs thereof, and certain naphthyl compounds | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | BMP1, BMP4, BMP2 | HRH3 1410/4885PSMB1 3072/4885PSMB5 2284/4885 |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | BMP1, BMP4, BMPR2 | HRH3 1002/4885PSMB1 3191/4885PSMB5 1819/4885 |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | HRH3 1922/4885PSMB1 1844/4885PSMB5 1199/4885 |
| US-10478443-B2 | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women | GPER1, ESR1, ESR2 | HRH3 857/4885PSMB1 2910/4885PSMB5 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.